KRAS and cancer: In particular, small molecules targeting KRAS G12C have been developed and are undergoing clinical trials14–16. Many of these agents have shown clinical success with one molecule receiving FDA accelerated approval earlier this year for treatment of KRAS G12C tumors in non-small cell lung carcinoma17. Despite this success, the strategy of selective inhibition has problems of being applicable to only a limited range of cancers integrated with personalized medicine and cannot be used to treat cancers that lack the specific mutation.